APR 0 1 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mattheakis et al.

Attorney Docket No.: CYTOP135X1

Application No.: 10/719,988

Examiner: UNASSIGNED

Filed: November 20, 2003

Group: 1645

Title: PREDICTING HEPATOTOXICITY USING

CELL BASED ASSAYS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on March 29, 2004 in an envelope addressed to the Contraissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450

Siamad.

Leslie Russel

INFORMATION DISCLOSURE STATEMENT 37 CFR §§1.56 AND 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a Continuation-in-Part of prior application U.S. Patent Application No. 10/623,486. This prior application is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure

Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP135X1).


Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

Jeffrey K. Weaver

Registration No. 31,314

P.O. Box 778 Berkeley, CA 94704-0778



			U.S. Pater	nt Documents		101	I E 11
Examiner		D () I	 			Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
	A1	4,818,710	04/04/89	Sutherland et al.	_		
	A2	4,922,092	05/01/90	Rushbrooke et al.			
	A3	4,959,301	09/25/90	Weaver et al.			
	A4	4,965,725	10/23/90	Ruttenberg			
	A5	5,287,272	02/15/94	Rubbenberg et al.	-	ļ	
	A6	5,326,691	07/05/94	Hozier			
	A7_	5,355,215	10/11/94	Schroeder et al.			
	A8	5,526,258	06/11/96	Bacus			
	A9	5,548,661	08/20/98	Price et al.			
	A10	5,655,028	08/05/97	Soll et al.			
	A11	5,733,721	03/31/98	Hemstreet III et al.			
	A12	5,741,648	04/21/98	Hemstreet III et al.			
	A13	5,776,748	07/07/98	Singhvi et al.			
	A14	5,790,692	08/04/98	Price et al.			
	A15	5,790,710	08/04/98	Price et al.			
	A16	5,804,436	09/08/98	Okun et al.			
		5,856,665	01/05/99	Price et al.			
		5,893,095	04/06/99	Jain et al.			
		5,919,646	07/06/99	Okun et al.			
		5,932,872	08/03/99	Price		1	
		5,962,250	10/05/99	Gavin et al.	_		
		5,976,825	11/02/99	Hochman			
		5,989,835	11/23/99	Dunlay et al.			
		5,991,028	11/23/99	Cabib et al.	-	-	
		5,995,143	11/30/99	Price et al.		 	
		6,007,996	12/28/99	McNamara et al.			
	A27		12/28/99	Greenberger et al.		<u> </u>	
		6,083,763	07/04/00	Balch			
	A29		08/15/00	Taylor		1	1
	A30		11/14/00	Friend et al.	<u> </u>	<u> </u>	
	A31		04/24/01	Marton et al.	 	 	
	A32	· · ·	02/05/02	Ramm et al.		+	
		5,162,990	11/10/92	Odeyale et al.		 	
	A34	 	04/06/93	Carlsson et al.			
Examiner] AJT	1112 37,217	104/00/23	Date Considered	1		1

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP135X1	10/719,988
Information Disclosure	Applicant:	
Statement By Applicant	Mattheakis et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub- class	Filing Date
Antiai		6,599,694	07/29/03	Elias	Olubb	Viass	Dute

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	B1	WO00/50872	08.31.00	WIPO				
	B2	WO00/33250	06.08.00	WIPO				
·	B3	WO00/49540	08.24.00	WIPO				
	B4	WO00/43820	07.27.00	WIPO				
- 	B5	WO00/03246	01.20.00	WIPO				
	B6	WO98/45704	10.15.98	WIPO				
	B7	WO99/05323	02.04.99	WIPO				
	B8	WO99/08091	02.18.99	WIPO				
	B9	WO99/17116	04.08.99	WIPO				
	B10	WO00/17643	03.30.00	WIPO	1			
	B11	WO 95/10036	13.04.05	WIPO				
	B12	WO 98/44333	08.10.98	WIPO				
	B13	WO 00/17624	30.03.00	WIPO	Ţ			
	B14	WO 00/17808	30.03.00	WIPO				
	B15	WO 93/21511	28.10.93	WIPO				
	B16	WO 94/11841	26.05.94	WIPO				
	B17	WO 95/22749	24.08.95	WIPO				
	B18	WO 96/01438	18.01.96	WIPO				
	B19	WO 96/09605	28.03.96	WIPO				
	B20	WO 97/20198	05.06.97	WIPO				
	B21	WO 97/40055	30.10.97	WIPO				
	B22	WO 97/43732	20.11.97	WIPO				
	B23	WO 97/45730	04.12.97	WIPO				
	B24	WO 98/05959	12.02.98	WIPO				
	B25	WO 98/35256	13.08.98	WIPO				
	B26	WO 98/38490	03.09.98	WIPO				
	B27	WO 00/06774	10.02.00	WIPO				
	B28	WO 00/26408	11.05.00	WIPO				
Examiner	•			Date Considered			-	

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP135X1	10/719,988
Information Disclosure	Applicant:	
Statement By Applicant	Mattheakis et al.	
	Filing Date	Group-
(Use Several Sheets if Necessary)	November 20, 2003	1645

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	B29	WO 99/39184	05.08.99	WIPO				
	B30	WO 00/70528	23.11.00	WIPO				
v=	B31	WO 00/60356	12.10.00	WIPO				
	B32	WO 00/29984	25.05.00	WIPO				
	B33	WO 87/02802	07.05.87	WIPO				Ī
	B34	WO 99/44062	02.09.99	WIPO				
	B35	WO 99/54494	28.10.99	WIPO				
	B36	WO 99/67739	29.12.99	WIPO				
	B37	WO 00/31534	02.06.00	WIPO				
	B38	WO 98/52018	19.11.98	WIPO				
	B39	0 317 139 B1	02.11.95	European				
	B40	0 468 705 A2	29.01.92	European				
	B41	EP 0 902 394 A1	17.03.99	European			T	

Other Documents

Examiner					
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication			
	C1	apur et al., "Design and Fabrication of Spatially Controlled Miniaturized Organ			
		Systems from Stem Cells", US provisional application serial number			
		60/127,339, filed April 1, 1999			
	C2	Adams et al., "Cell Patterning on Glass and Polymeric Substrates", US			
		Provisional application serial number 60/138,119, filed June 7, 1999			
	C3	Dunlay et al., "Data Management and Presentation Methods", US			
		Provisional application serial number 60/140,240, filed June 21, 1999			
	C4	Blankenstein et al., "Modular concept of a laboratory on a chip for chemical and			
		biochemical analysis, © 1998, Biosensors & Bioelectronics, Vol. 13., No. 3-4, pp.			
		427-438.			
	C5	István Cseke, "A Fast Segmentation Scheme for White Blood Cell Images",			
		© 1992 IEEE, pp. 530-533.			
	C6	Hofland et al., "Role of Tumor-Derived Fibroblasts in the Growth of Primary			
		Cultures of Human Breast-Cancer Cells: Effects of Epidermal Growth Factor and the			
		Somatostatin Analogue Octreotide", © 1995 Wiley-Liss, Inc., Publication of the			
		International Union Against Cancer, pp. 93-99.			
Examiner		Date Considered			

Form 1449 (Modified)	Atty Docket No. CYTOP135X1	Application No.: 10/719,988
Information Disclosure Statement By Applicant	Applicant: Mattheakis et al.	·
Statement by Applicant	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

		Other Documents		
Examiner				
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication		
	C7	Boyce et al., "Systems and Methods to Achieve Integrated Presentation of Summary Statistics, Detail Measurements, and Raw Images While Maintaining Efficient Use of Storage Media Through Separation of the Data in an Integrated Data Management and Presentation System", US provisional application serial number 60/108,291, filed November 13, 1998		
	C8	Boyce et al., "Data Management and Presentation Methods", US Provisional application serial number 60/142,375, filed July 6, 1999		
	C9	Boyce et al., "Data Management and Presentation Methods", US Provisional application serial number 60/142,646, filed July 6, 1999		
	C10	Roger James, "A Pulsed Polarimeter", US Provisional application serial Number 60/110,643, filed December 1, 1998		
	C11	Wang et al., "Database for Storage, Retrieval, and Analysis of Cellular Information", US Provisional application serial number 60/120,801, filed February 19, 1999		
	C12	Printout from Q3DM Website (www.Q3DM.com), printed on March 1, 2001, 30 pages.		
	C13	9, 2001, 24 pages.		
	C14	Pauwels, et al., "Determination of the Mechanism of Action of Anticancer Drugs by Means of the Computer-Assisted Microscope Image Analysis of Feulgen-Stained Nuclei", J. Pharmacological and Toxicological Methods, 37: 105-115 (1997).		
	C15	Pauwels, et al., "Monitoring of chemotherapy-induced morphonnuclear modifications by means of digital cell-image analysis", I. Cancer Res. Clin. Oncol., 119: 533-540 (1993).		
		Pauwels, et al., "In Vitro Digital Cell Image Analysis of Morphonuclear Modifications Induced by Natural DNA-Interacting Anticancer Drugs in Three Neoplastic Cell Lines", Meth. Find. Exp. Clin. Pharmacol, 17(3): 151-162 (1995).		
	 C17 Pauwels, et al., "The Application of Computerized Analysis of Nuclear Images a Multivariate Analysis to the Understanding of the Effects of Antineoplastic Ager and Their Mechanism of Action", Meth. Find. Exp. Clin Pharmacol, 15(2): 113-1 (1993). C18 Pauwels, et al., "Combination of Computerized Morphonuclear and Multivariate Analysis to Characterize In Vitro the Antineoplastic Effect of Alkylating Agents' Pharmacol. and Toxicol. Methods, 33(1): 34-45 (1995). 			
Examiner	·	Date Considered		

Form 1449 (Modified)	Atty Docket No. CYTOP135X1	Application No.: 10/719,988
Information Disclosure Statement By Applicant	Applicant: Mattheakis et al.	·
	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

		Other Documents
Examiner		
Initial	No.	
	C19	
		induced Angiogenesis: IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1
		and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion, (1999) Clin.
	<u> </u>	Cancer Res. 5: 189-196.
	C20	
		index in apical conifer meristems", October 1998, Journal of Experimental Botany,
		Vol. 49, No. 327, pp. 1749-1756.
	C21	
		flows in capillary networks", (1999) Proc. Natl., Acad. Sci USA, 96:5545-5548.
	C22	
		Pharmacology of Cancer", Science, 275: 343-349 (January 17, 1997).
	C23	
		Drugs", (1997) Science 278:1064-1068.
	C24	
		Transformed by Principal Component Analysis", Proceedings of SPIE, Bellingham,
	<u> </u>	Spie, US (1996), Vol. 2670, pp. 50-61.
	C25	, , , , , , , , , , , , , , , , , , ,
	l	Structures in Fluorescence Microscopy Images", Rapid Communications, Cytometry
	<u> </u>	33:366-375 (1998).
	C26	
		Bottlenecks in the Drug Discovery Process", © 1997 The Society for Biomolecular
		Screening, Inc., Journal of Biomolecular Screening, Vol. 2, No. 4, 1997, pp. 249-258.
	C27	
		cytometry in breast cancer", 1993, pp.795-800.
	C28	· · · · · · · · · · · · · · · · · · ·
		March 1998, Vol. 16, pp.135-140.
	C29	
		immortalized human hepatocytes", Science, Vol. 287, February 18, 2000, 1258-1262.
	C30	
	ŀ	extrahepatic diseases, The Mount Sinai Journal of Medicine", Vol. 67, No. 1, January
		2000, pp. 84-94.
	C31	
		Science, Vol. 190, 1975, pp. 794-5.
	C32	
		Cholestasis", Progress in Liver Diseases, (1986), pp. 161-178.
Examiner		Date Considered

Form 1449 (Modified)	Atty Docket No. CYTOP135X1	Application No.: 10/719,988
Information Disclosure Statement By Applicant	Applicant: Mattheakis et al.	
John Stranger	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

		Other Doc	uments		
Examiner					
Initial No. Author, Title, Date, Place (e.g. Journal) of Publication					
C3		McMillian, et al., "Nile Red Binding to HepG2 Cells: An Improved Assay for In			
		Vitro Studies of Hepatosteatosis	s", In Vitro & Molecular Toxicology, Volume 14,		
		Number 3, 2001, pp. 177-190.			
	C34		Alters Bile Canalicular Contractility In Primary		
		Monalayer Cultures Of Rat Liver", Gastroenterology, (1983), 85, pp.245-253.			
	C35		alteration as a potential marker for cholestasis: a		
		study in isolated rat hepatocyte	couplets", Toxicology, 73, (1992), pp. 269-279.		
	C36		on Of Nile Red, A Fluorescent Hydrophobic Probe,		
		For The Detection Of Neutral Lipid Deposits In Tissue Sections: Comparison With			
			hem, March 1985, Vol. 33, No. 8, pp. 833-836.		
	C37		: A Selective Fluorescent Stain For Intracellular Lipid		
		Droplets," J Cell Biol, 1985, Vo			
	C38				
		Toxicol, 2002, 21(5): p. 253-262.			
	C39	Amacher, D.E., et al., "Tetracycline-Induced Steatosis In Primary Canine Hepatocyte			
	_	Cultures," Fundam Appl Toxico			
	C40		paratus for Investigating Side Effects", U.S. Patent		
			atty. Docket CYTOP110), filed July 16, 2003.		
	C41				
	C42	Application No. 09/789,595, (Atty. Docket CYTOP011), filed February 20, 2001.			
	Method for a Predicitive Cellular Bioninformatics,"				
		U.S. Patent Application No. 09/310,879 (Atty. Docket CYTOP006), filed on I			
		1999.			
	C43		tem Including Computer For Predicitive Cellular		
		Bioninformatics," U.S. Patent Application No. 09/311,996, (Atty. Docket			
		CYTOP007), entitled filed on May 14, 1999.			
	C44				
		Patent Application No. 09/311,890 (Atty. Docket CYTOP008), filed on May 14,			
	 	1999.			
C45 Vaisberg, et al., "Image Analysis Of The Golgi Complex", U.S. Patent A					
	_		CYTOP012), filed on February 20, 2001.		
	C46	Coleman et al., "Methods and A	Apparatus For Characterising Cells And Treatments",		
		US Patent Application No. 10/615,116, (Atty. Docket CYTOP111), filed July 7,			
		2003.	T. C. 11 C.		
	C47		Information Contained In Cell Images", U.S. Patent		
Application No. 09/792,013, (Atty. Docket CYTOP013), filed Februa					
Examiner			Date Considered		

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP135X1	10/719,988
Information Disclosure	Applicant:	
Statement By Applicant	Mattheakis et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

		Other Doc	uments			
Examiner						
Initial No. Author, Title, Date, Place (e.g. Journa						
· -	C48	Serbouti, et al., "Image Segmer	ntation and Classification Methods to Detect			
			"I Conf. of IEEE Eng. In Medicine & Biology Soc.,			
		Vol. 13, No. 1, pp. 0260-0261.				
	C49	Vaisberg et al., "Classifying Ce	ells Based on Information Contained In Cell Images",			
		U.S. Application No. 09/729,75	54, (Atty. Docket CYTOP005), filed December 4,			
		2000.				
	C50		g Biological Stimuli By Response Curves," U.S.			
		Patent Application No. 09/789,	595, (Atty. Docket CYTOP140), filed February 20,			
		2001.				
	C51	Rubas et al., "An Integrated Me	ethod to Determine Epithelial Transport and			
		Bioactivity of Oral Drug Candi	dates in Vitro", Rapid Communication,			
		Pharmaceutical Research, Vol.	13, No. 1, 1996, pp. 23-26.			
	C52		of Dense Leukocyte Clusters", IEEE Workshop on			
			nedical Image Analysis, 2001, pp. 221-227.			
	C53		ershed Algorithms to the Segmentation of Clustered			
		Nuclei", Cytometry, Vol. 28, 1				
	C54		tomated 3-D Image Analysis of Cell Populations			
			by", Cytometry, Vol. 25, 1996, pp. 221-234.			
	C55		Blom, et al., "Regional loss of the mitochondrial membrane potential in the			
			by externalization of phosphatidyl serines at that			
		specific site during apoptosis", JBC Papers in Press, published on January 21, 2003,				
		pp. 1-36.				
	C56		lagenase-3 Expression in Human Breast Carinomas Is			
			l Cell Interactions", Cancer Research 57, November 1,			
		1997, pp. 4882-4888.				
	C57		s of Hepatotoxicity", Hepatotoxixity: The Adverse			
		Effects of Drugs and Other Chemicals on the Liver, Section I, General				
		Considerations, 2 nd Edition, 19				
	C58					
		Hepatotoxixity: The Adverse Effects of Drugs and Other Chemicals on the Liver,				
			ons, 2 nd Edition, 1999, pp. 111-145.			
	C59					
			emicals on the Liver, Section II, General			
		Considerations, 2 nd Edition, 19	99, pp. 201-228.			
		<u> </u>				
Examiner			Date Considered			

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP135X1	10/719,988
Information Disclosure	Applicant:	
Statement By Applicant	Mattheakis et al.	
1	Filing Date	Group
(Use Several Sheets if Necessary)	November 20, 2003	1645

Examiner Initial No. Author, Title, Date, Place (e.g. Journal) of Publication C60 Zimmerman, H.J., "Toxic Cholestasis", Hepatotoxixity: The Adverse Eff Drugs and Other Chemicals on the Liver, Section II, General Consideration Edition, 1999, pp. 295-323.	ects of ons, 2 nd
C60 Zimmerman, H.J., "Toxic Cholestasis", Hepatotoxixity: The Adverse Eff Drugs and Other Chemicals on the Liver, Section II, General Consideration	ects of ons, 2 nd
Drugs and Other Chemicals on the Liver, Section II, General Consideration	ects of ons, 2 nd
Examiner Date Considered	